Literature DB >> 15561215

Successful case of adult ABO-incompatible liver transplantation: beneficial effects of intrahepatic artery infusion therapy: a case report.

Y Nakamura1, N Matsuno, H Iwamoto, T Yokoyama, K Kuzuoka, Y Kihara, S Taira, T Sagara, Y Jojima, O Konno, J Tashiro, I Akashi, K Hama, K Narumi, T Iwahori, M Uchiyama, K Tanaka, T Nagao.   

Abstract

BACKGROUND: In Japan ABO-incompatible liver transplantation has been done on >100 occasions up to 2003. However, <30% are cases involving adults. The difficultly of ABO-incompatible liver transplantation is associated with the high frequency of humoral rejection and local disseminated intravascular coagulation (DIC), leading to many postoperative complications. We report a successful case of adult ABO-incompatible liver transplantation with the use of an intrahepatic artery infusion.
METHODS: A 36-year-old man with Wilson disease, underwent living donor liver transplantation from an ABO-incompatible donor. The immunosuppressive therapy included multiple perioperative plasmaphereses, splenectomy, and treatment with tacrolimus, methylprednisolone, and cyclophosphamide. The dose and blood level of tacrolimus were the same as in ABO-compatible cases. In addition to these therapies, we administered an intrahepatic arterial infusion with prostaglandin (PG) E1 alone.
RESULTS: After perioperative plasmapheresis and cyclophosphamide, antidonor blood group antibody titers remained undiluted and without vascular complications throughout the postoperative course, but there was a tendency for bleeding that continued for 10 days after transplantation. On postoperative day 10, a reexploration was performed for intraabdominal bleeding. During another operation on postoperative day 59 a biloma was found and drained. The patient has now survived for 120 days after transplantation with normal liver function.
CONCLUSIONS: Beneficial effect of intrahepatic artery infusion with PGE1 seems to be useful in adult ABO-incompatible liver transplantation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15561215     DOI: 10.1016/j.transproceed.2004.08.094

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  7 in total

1.  Liver transplantation: Evading antigens-ABO-incompatible liver transplantation.

Authors:  Ali Zarrinpar; Ronald W Busuttil
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-11-18       Impact factor: 46.802

Review 2.  Management of ABO-incompatible living-donor liver transplantation: past and present trends.

Authors:  Vikram Raut; Shinji Uemoto
Journal:  Surg Today       Date:  2011-02-23       Impact factor: 2.549

3.  Treatment Experience of Severe Abdominal Infection after Orthotopic Liver Transplantation.

Authors:  Y-G Wang; J-S Wu; B Jiang; J-H Wang; C-P Liu; C Peng; B-Z Tian
Journal:  West Indian Med J       Date:  2015-05-15       Impact factor: 0.171

4.  Risk factor for ischemic-type biliary lesion after ABO-incompatible living donor liver transplantation.

Authors:  Jun Bae Bang; Bong-Wan Kim; Young Bae Kim; Hee-Jung Wang; Hyun Yeong Lee; Joohyun Sim; Taegyu Kim; Kyeong Lok Lee; Xu-Guang Hu; Wei Mao
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

5.  Anaesthetic implications and transfusion practices in ABO incompatible living donor liver transplantation: Case series.

Authors:  Sindhu Balakrishnan; Lakshmi Kumar; Divya Daniel; Sudhindran Surendran
Journal:  Indian J Anaesth       Date:  2021-04-15

Review 6.  Recipient outcomes after ABO-incompatible liver transplantation: a systematic review and meta-analysis.

Authors:  Jian Wu; Sunyi Ye; Xiaofeng Xu; Haiyang Xie; Lin Zhou; Shusen Zheng
Journal:  PLoS One       Date:  2011-01-25       Impact factor: 3.240

Review 7.  Outcomes after liver transplantation in accordance with ABO compatibility: A systematic review and meta-analysis.

Authors:  Eung Chang Lee; Seong Hoon Kim; Sang-Jae Park
Journal:  World J Gastroenterol       Date:  2017-09-21       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.